FDA approves Roche’s Gavreto to treat metastatic RET fusion-positive NSCLC

This article was originally published here

Gavreto, a once-daily and oral precision therapy, will help selectively target RET alterations such as fusions and mutations irrespective of the tissue of origin. Roche’s wholly-owned member Genentech

The post FDA approves Roche’s Gavreto to treat metastatic RET fusion-positive NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply